Pharmaceuticals
WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry
* End-to-end Green CRDMO solutions to enable global clients for broader positive impact * Span from biologics research, development, manufacturing, and overall operations * Integration with lean management and digitalization for continuous excellence * A comprehensive ecosystem featuring ...
2025-09-09 18:00
2849
Nobel Laureate Headlines Global Discussion in Cell & Gene Therapy in London
PISCATAWAY, N.J., Sept. 8, 2025 /PRNewswire/ -- Cell and gene therapies (CGT) are advancing rapidly and are reshaping the future of medicine. From CRISPR-based genome editing to new applications of in vivo and ex vivo cell therapies, scientific breakthroughs are increasingly moving from the labor...
2025-09-08 20:49
1300
Remplir™ Study Delivers Compelling 81% Success Rate
Data to support US sales roll out and EU + UK regulatory submissions * Interim results from a new Remplir™ study demonstrated a compelling overall treatment success rate of 81.1% following nerve repair procedures. * Real World Evidence (RWE) patient data collected in the study confirms Ortho...
2025-09-08 17:32
1600
Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332
* The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332 * In the North American patients, the OS HR was 0.70 * The HARMONi trial has already demonstrated clinically meaningful and statistically significant progression-free survival (PFS) ...
2025-09-07 18:08
1813
Senhwa Biosciences CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value
TAIPEI and SAN DIEGO, Sept. 5, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has granted IND clearance for its innovative drug candidate Pidnarulex(CX-5461) ina Phase1b/2 clin...
2025-09-05 16:46
1605
Immunofoco Earns Spot on Forbes Asia 100 to Watch 2025 List for Leading New Wave in Solid Tumor Cell Therapy
SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- Immunofoco, a clinical-stage biotechnology company, focused on developing novel cell therapies for solid tumors, has been selected for the prestigious "Forbes Asia 100 to Watch 2025" list. This annual list, compiled by the editors of Forbes Asia, spotlights...
2025-09-05 16:09
2460
Global Bio Conference 2025 kicks off in Seoul, charting biotech's future
SEOUL, South Korea, Sept. 3, 2025 /PRNewswire/ -- This is an article published in The Korea Herald: The Ministry of Food and Drug Safety announced Wednesday that it kicked off Global Bio Conference 2025, under the theme "Bio, Navigating Infinite Possibilities." The conference will be held from...
2025-09-03 20:00
1665
BON Announces Identification of Promising Weight-Managing Compounds from Tea via AI-Powered New Drug R&D Platform
XI'AN, China, Sept. 2, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a groundbreaking identification of a class of natural polyphenolic compounds f...
2025-09-02 20:30
3739
SK bioscience Submits IND for Phase 3 Trial of 2-Dose Varicella Vaccine Reflecting Global Standard Shift
* Approximately 800 children aged 12 months to 12 years in Korea and abroad, aiming for completion by 2027 * Rising demand for 2-dose regimen as international standards amid projected global market growth toUSD 6.3 billion by 3034 * SKBS continues strategic R&D to enhance global vaccine comp...
2025-09-02 19:00
2131
Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights
SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge the gap between small molecules and large biologics. Positioned between the two, cyclic peptides combine...
2025-09-02 17:52
1553
Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy
HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study evaluating ivonescimab, in combination with standard therapy, against durvalumab (PD-L1) combination the...
2025-09-02 16:00
1438
AMI Pharm's AYP-101 Shows Promise in Phase 2 Trial, Signaling a Breakthrough in Nonsurgical Fat Reduction
* AMI Pharm's 'AYP-101' Sets to Become a New Leader in Nonsurgical Fat Reduction with Phase 2 Trial Success * 'AYP-101,' a Promising Nonsurgical Solution, Has Its Clinical Results Published in Clinical Therapeutics * 'AYP-101' Demonstrates Superior Safety and Efficacy, Poised to Change the ...
2025-09-01 21:00
1496
Jenscare, releases 2025H1 interim results
BEIJING, Sept. 1, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with TTVR breakthroughs, achieved milestones in its product portfolio globally, and just released its interim results for 2025H1 endedJune 30, 2025...
2025-09-01 13:00
5154
Jacobio Pharma Announces 2025 Interim Results
BEIJING and SHANGHAI and BOSTON, Aug. 29, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) today announced its interim results for the six months endedJune 30, 2025. During the reporting period, the Company achieved revenue of RMB45.7 million, representing a 100% increase compared with the same per...
2025-08-30 00:25
5588
YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market
* Strategic Move Positions YD Bio Limited for Accelerated Innovation and Market Expansion * Trading of common stock and warrants of the new public company, YD Bio Limited, is expected to commence on the Nasdaq Global Market onAugust 29, 2025, under the ticker symbols "YDES" and "YDESW" NEW YO...
2025-08-29 19:30
2866
Celaid Therapeutics have executed a collaborative research agreement with AGC on Expansion and Functional Evaluation of iPSC-HSPCs
TOKYO, Aug. 28, 2025 /PRNewswire/ -- Celaid Therapeutics Inc. ("Celaid") have executed a collaborative research agreement with AGC Inc. ("AGC") to advance iPS cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs). The collaboration aims to combine Celaid's proprietary platform of hema...
2025-08-28 22:00
1256
D3 Bio, Inc. Announces FDA Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for the Treatment of Patients with KRAS G12C-Mutated Cancers
* Breakthrough Therapy Designation was granted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior treatment with platinum-based chemotherapy and anti-PD-(L)1 antibody but have not been previously treate...
2025-08-28 21:00
3473
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee
BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious d...
2025-08-28 20:00
2834
Ascletis Announces Favorable and Differentiated Pharmacokinetic Profile of ASC30 Oral Once-Daily Tablet in Its U.S. Phase Ib Multiple Ascending Dose Study
- ASC30 oral once-daily tablet demonstrated approximately 2.3-fold to 3.3-fold greater drug exposure than orforglipron in a cross-trial comparison. - Higher drug exposure and favorable tolerability profile positions ASC30 oral once-daily tablet favorably compared to orforglipron...
2025-08-28 07:45
1322
Fangzhou Posts Strong 1H Revenue and Profit as Physician Network and User Base Expand
HONG KONG, Aug. 27, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, reported a profitable first half of 2025, supported by an expanding user base, higher operating efficiency, and accelerated deployment of AI across...
2025-08-27 23:09
2418
Week's Top Stories
Most Reposted
Agoda Launches Free Global eSIMs for VIP Diamond Members
[Picked up by 322 media titles]
2026-02-10 14:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Blackpanda Japan Announces Strategic Partnership with SoftBank to Strengthen Cyber Incident Response in Japan
[Picked up by 299 media titles]
2026-02-10 13:31Rockwell Automation Strengthens Industrial Cybersecurity with New Security Operations Center in Singapore
[Picked up by 299 media titles]
2026-02-09 10:00
Carro unveils quirky generative AI ad campaign highlighting its 'Surprisingly Short' AI-enabled car-selling process
[Picked up by 296 media titles]
2026-02-11 11:00
Most Read
Angel Yeast Indonesia Project: Strengthening Foundations through Technical Training and Building Consensus through Cultural Exchange
2026-02-07 09:31
9294
DaVinci Gourmet Named Title Sponsor of The World's 100 Best Coffee Shops 2026, to Be Unveiled in Madrid
2026-02-06 21:28
8492
/C O R R E C T I O N -- Fairland Group - iGarden/
2026-02-08 17:31
8273
